RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Cagrilintide is a synthetic, long-acting analogue of amylin, a hormone involved in the body’s response to food. Researchers have studied it both independently and alongside semaglutide in a combination called CagriSema. Randomized human trials have reported changes in body weight, but the results depend on the study population, treatment, duration, and analysis method. Findings for the combination cannot be attributed to cagrilintide alone, and clinical trial results do not establish equivalent effects or safety for separately supplied research products. [1–4]
WHAT IS CAGRILINTIDE?
Cagrilintide is an engineered peptide based on human amylin. Its development involved changes intended to improve stability, reduce the tendency of amylin molecules to form fibrils, and prolong biological activity. A fatty-acid attachment supports reversible binding to albumin, a protein in the bloodstream. [1]
The original development paper describes activity at both amylin and calcitonin receptors. Cagrilintide therefore should not be described as acting exclusively at one amylin receptor subtype. Its receptor profile is also different from that of semaglutide, which acts through the GLP-1 receptor. [1]
WHY IS AMYLIN SIGNALING OF INTEREST?
Amylin is produced by pancreatic beta cells and released alongside insulin. It participates in signaling associated with food intake and satiation—the processes that help bring a meal to an end.
Researchers developed cagrilintide to investigate whether prolonged activity in this signaling system could influence body-weight regulation. Its molecular design and receptor activity explain the research rationale; clinical outcomes require separate evidence from controlled trials. [1,2]
WHAT DID THE CAGRILINTIDE-ONLY TRIAL FIND?
A 2021 phase 2 trial randomly assigned 706 adults with overweight or obesity and without diabetes to several cagrilintide groups, liraglutide, or placebo. The treatment period lasted 26 weeks. [2]
Using an analysis that estimated outcomes assuming participants continued their assigned treatment, average body-weight reductions ranged from 6.0% to 10.8% across the cagrilintide groups, compared with 3.0% for placebo. An analysis that considered outcomes regardless of treatment adherence produced similar findings. [2]
These were group averages under trial conditions, not guaranteed individual outcomes. Gastrointestinal adverse events, including nausea, constipation, and diarrhea, were more frequent with cagrilintide than with placebo. [2]
HOW IS CAGRILINTIDE DIFFERENT FROM CAGRISEMA?
CagriSema combines cagrilintide with semaglutide. Studying the two together allows researchers to investigate complementary biological pathways, but it creates a distinction that must remain clear when discussing results.
In the 2025 REDEFINE 1 trial, 3,417 adults without diabetes were assigned to the combination, semaglutide alone, cagrilintide alone, or placebo. All groups received lifestyle interventions. At 68 weeks, estimated average body-weight reductions were 20.4% with the combination, 14.9% with semaglutide, 11.5% with cagrilintide, and 3.0% with placebo. These estimates assessed outcomes regardless of treatment discontinuation. [3]
The 20.4% figure therefore belongs to the combination, not cagrilintide alone. It also should not be directly compared with percentages from other trials without considering differences in participants, duration, and analysis methods.
WHAT DID RESEARCH IN TYPE 2 DIABETES SHOW?
REDEFINE 2 studied 1,206 adults with overweight or obesity and type 2 diabetes. It compared CagriSema with placebo over 68 weeks, alongside lifestyle intervention. Estimated average body-weight reductions were 13.7% with the combination and 3.4% with placebo. [4]
This trial studied a different population from REDEFINE 1. Its results should not be interpreted as evidence that individuals with or without diabetes will experience a particular outcome. Because REDEFINE 2 did not include a cagrilintide-only group, it cannot isolate cagrilintide’s individual contribution. [4]
WHAT DO THE STUDIES SAY ABOUT TOLERABILITY?
Gastrointestinal symptoms were common in the combination trials. In REDEFINE 1, gastrointestinal adverse events occurred in 79.6% of combination recipients and 39.9% of placebo recipients; they were generally temporary and mild to moderate. [3]
In REDEFINE 2, adverse events led to treatment discontinuation in 8.4% of combination recipients, compared with 3.0% receiving placebo. These findings belong alongside the weight-change results when assessing the research. [4]
WHAT REMAINS UNCERTAIN?
The studies summarized here establish biological and clinical activity under defined research conditions. They do not answer every question about long-term outcomes, uncommon adverse effects, or responses in populations not adequately represented in the trials.
Body-weight change is also a specific endpoint. It should not automatically be translated into claims about longevity, cardiovascular protection, or other outcomes that a particular trial did not evaluate.
Finally, the identity of a named molecule does not establish equivalence between products. Clinical trial formulations and separately supplied laboratory materials may differ in purity, stability, composition, and manufacturing controls. Published trial findings do not validate those characteristics for any product sold on this website.
REFERENCES
Some study titles are shortened for readability. Each link identifies the original source.
[1] Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021;64(15):11183–11194.
https://doi.org/10.1021/acs.jmedchem.1c00565
[2] Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. The Lancet. 2021;398(10317):2160–2172.
https://doi.org/10.1016/S0140-6736(21)01751-7
[3] Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393:635–647.
https://doi.org/10.1056/NEJMoa2502081
[4] Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393:648–659.